Last reviewed · How we verify
SHR-1707
At a glance
| Generic name | SHR-1707 |
|---|---|
| Sponsor | Shanghai Hengrui Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients. (PHASE1)
- A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease (PHASE1)
- Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients (PHASE2)
- A Study of SHR-1707 in Healthy Young Adult and Elderly Subjects (PHASE1)
- A Trial of SHR-1707 in Healthy Young Adult and Elderly Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHR-1707 CI brief — competitive landscape report
- SHR-1707 updates RSS · CI watch RSS
- Shanghai Hengrui Pharmaceutical Co., Ltd. portfolio CI